Company: GANX
Filing Date: 2025-11-28
Form Type: 424B5
Source: 0001104659-25-116944
Chunk: 2

Company: Gain Therapeutics, Inc.
Filing Date: 2025-11-28
Form: 424B5
Chunk 2
---
 | ​ | ​ | ​ | 23 | ​ | ​ |
| ​ | PLAN OF DISTRIBUTION                                 | ​ | ​ | ​ | ​ | 25 | ​ | ​ |
| ​ | LEGAL MATTERS                                        | ​ | ​ | ​ | ​ | 29 | ​ | ​ |
| ​ | EXPERTS                                              | ​ | ​ | ​ | ​ | 29 | ​ | ​ |
| ​ | ADDITIONAL INFORMATION                               | ​ | ​ | ​ | ​ | 30 | ​ | ​ |
| ​ | INCORPORATION OF CERTAIN INFORMATION BY REFERENCE    | ​ | ​ | ​ | ​ | 31 | ​ | ​ |

S-i

TABLE OF CONTENTS

### ABOUT THIS PROSPECTUS SUPPLEMENT
This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a shelf registration process. Under the shelf registration process, we may offer shares of our common stock having an aggregate offering price of up to $50,000,000 from time to time under this prospectus supplement at prices and on terms to be determined by market conditions at the time of offering.

This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of shares of our common stock and adds to and updates the information contained in the accompanying prospectus. The second part, the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus, you should rely on the information in this prospectus supplement.

This prospectus supplement and the accompanying prospectus relate to the offering of our common stock. Before buying any shares of common stock that we are offering, we urge you to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated by reference as described under the heading “ Incorporation of Certain Information by Reference ” in this prospectus supplement and the accompanying prospectus and the information in any free writing prospectus that we may authorize for use in connection with this offering. These documents contain important information that you should consider when making your investment decision.

This prospectus supplement describes the specific terms of the common stock we are offering and also adds to and updates information contained in the accompanying prospectus